Section Arrow
Quote
REGN.NASDAQ
- Regeneron Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/21 06:41 EDT
Pre Market
Last
 546.5
+3.98 (+0.73%)
Bid
543.6
Ask
554
High 547 
Low 542.52 
Volume 55 
Regular Hours
Last
 542.52
-7.48 (-1.36%)
Day High 
550.885 
Prev. Close
550 
1-M High
575.13 
Volume 
1.31M 
Bid
543.6
Ask
554
Day Low
541.5 
Open
550 
1-M Low
503.25 
Market Cap 
59.38B 
Currency USD 
P/E 14.01 
%Yield 0.32 
10-SMA 552.98 
20-SMA 537.86 
50-SMA 544.53 
52-W High 1,211.1999 
52-W Low 476.4869 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
39.34/40.04
Enterprise Value
62.09B
Balance Sheet
Book Value Per Share
272.19
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
14.20B
Operating Revenue Per Share
121.31
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.16 -0.915 -6.50%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.21 +0.37 +6.34%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed：2025/07/21 06:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.